Loading cancer entity…
Loading cancer entity…
Clinical trials
136 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04049669 | Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG | active not recruiting | Phase 2 | 130 | Theodore S. JohnsonOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06466798 | Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies | withdrawn | Phase 1 | 0 | Jeffrey TreiberOTHER | 0 | Jan 8, 2026 | clinicaltrials |
| NCT04541082 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | recruiting | Phase 1 | 102 | Jazz PharmaceuticalsINDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT03500991 |
Data updated 22 days agoSource updated Jan 8, 2026source: clinicaltrials
| active not recruiting |
| Phase 1 |
| 10 |
| Seattle Children's HospitalOTHER |
| 1 |
| Dec 17, 2025 |
| clinicaltrials |
| NCT03638167 | EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors | completed | Phase 1 | 11 | Seattle Children's HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05259605 | Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification | recruiting | — | 1,650 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 12 | Dec 17, 2025 | clinicaltrials |
| NCT02238899 | Multicenter Register for Children and Young Adults With Intracranial Localized Medulloblastoma, CNS-PNET or Ependymoma | completed | — | 354 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06521567 | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | active not recruiting | Phase 1 / Phase 2 | 83 | GlaxoSmithKlineINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT02162732 | Molecular-Guided Therapy for Childhood Cancer | completed | N/A | 186 | Giselle ShollerOTHER | 2 | Nov 3, 2025 | clinicaltrials |
| NCT01165632 | Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma | completed | Early Phase 1 | 24 | Mayo ClinicOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT01295944 | Carboplatin and Bevacizumab for Recurrent Ependymoma | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Aug 5, 2025 | clinicaltrials |
| NCT06038760 | Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)(PEAR-GLIO) | terminated | — | 12 | Ourotech, Inc.INDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT03128047 | HUMC 1612: Optune NovoTTF-200A System | completed | Phase 1 | 7 | Hackensack Meridian HealthOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT01288235 | Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation | completed | Phase 2 | 100 | Massachusetts General HospitalOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT03095248 | Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors(SEL-TH-1601) | terminated | Phase 2 | 10 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT06779487 | Systemic Biomarkers to Predict Radiation-Induced Neurocognitive Decline(BIO-RIN) | recruiting | — | 200 | Tata Memorial CentreOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT03572530 | Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa Ependymoma(5-AZA) | completed | Phase 1 | 3 | The University of Texas Health Science Center, HoustonOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT06323408 | Integrated Analysis of Therapy Response and Resistence in Embryonal Tumors and Gliomas(BZKF-AYA) | not yet recruiting | — | 72 | University Hospital RegensburgOTHER | 0 | Mar 25, 2025 | clinicaltrials |
| NCT00638898 | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT02722512 | Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine | terminated | Phase 1 | 10 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT03220035 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 2 | Jan 27, 2025 | clinicaltrials |
| NCT03233204 | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2024 | clinicaltrials |
| NCT01247922 | Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205 | terminated | Phase 2 | 4 | OSI PharmaceuticalsINDUSTRY | 3 | Dec 6, 2024 | clinicaltrials |
| NCT04648462 | Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology | recruiting | — | 1,500 | Maastricht Radiation OncologyOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT03990597 | StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation Therapy to the Brain or Spinal Cord | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06499636 | In Vitro Models From Pediatric Brain Tumors(PBTS23) | not yet recruiting | — | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT06485908 | Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and Ependymoma(MEPENDAX) | not yet recruiting | Phase 1 / Phase 2 | 40 | Assistance Publique Hopitaux De MarseilleOTHER | 0 | Jul 3, 2024 | clinicaltrials |
| NCT03434262 | SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors | completed | Phase 1 | 68 | St. Jude Children's Research HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT02155920 | Everolimus for Children With Recurrent or Progressive Ependymoma | completed | Phase 2 | 11 | University of Texas Southwestern Medical CenterOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT03043391 | Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children | completed | Phase 1 | 8 | Istari Oncology, Inc.INDUSTRY | 1 | Apr 8, 2024 | clinicaltrials |
| NCT03206021 | COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors(COZMOS) | completed | Phase 1 | 31 | The Hospital for Sick ChildrenOTHER | 3 | Apr 5, 2024 | clinicaltrials |
| NCT04408092 | Study of the Effect of GM-CSF on Macrophages in Ependymoma | completed | Early Phase 1 | 6 | University of Colorado, DenverOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT00019578 | Stereotactic Radiosurgery in Treating Patients With Brain Tumors | completed | Phase 1 | — | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 31, 2023 | clinicaltrials |
| NCT00634231 | A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors | completed | Phase 1 | 8 | Candel Therapeutics, Inc.INDUSTRY | 1 | Aug 25, 2023 | clinicaltrials |
| NCT03860376 | Ex Vivo Drug Sensitivity Testing and Mutation Profiling | completed | — | 25 | Florida International UniversityOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT04730349 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer(PIVOT IO 020) | terminated | Phase 1 / Phase 2 | 15 | Bristol-Myers SquibbINDUSTRY | 6 | Mar 24, 2023 | clinicaltrials |
| NCT05672043 | Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China(GRIPP) | recruiting | — | 400 | Beijing Tiantan HospitalOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT03727841 | Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Jul 27, 2022 | clinicaltrials |
| NCT02013297 | Study of SBRT Efficacy on Intra and Extra -Cranial Tumors or Metastasis in Pediatrics Population (SBRT Pediatrics)(SBRT) | completed | N/A | 61 | Centre Leon BerardOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT00003479 | Antineoplaston Therapy in Treating Patients With Ependymoma | terminated | Phase 2 | 9 | Burzynski Research InstituteOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT03387020 | Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors | completed | Phase 1 | 22 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Aug 27, 2021 | clinicaltrials |
| NCT01125046 | Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas | completed | Phase 2 | 50 | Northwestern UniversityOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT01024907 | Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas | completed | Phase 1 / Phase 2 | 23 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT02271711 | Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors | completed | Phase 1 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT02502708 | Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors | completed | Phase 1 | 81 | NewLink Genetics CorporationINDUSTRY | 1 | Jun 4, 2020 | clinicaltrials |
| NCT01331135 | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors(Aflac ST0901) | completed | Phase 1 | 18 | Emory UniversityOTHER | 1 | May 29, 2020 | clinicaltrials |
| NCT02684071 | Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors | terminated | Phase 2 | 3 | Nicklaus Children's Hospital f/k/a Miami Children's HospitalOTHER | 1 | Jan 10, 2020 | clinicaltrials |
| NCT01117155 | A Pilot Study Evaluating 18F-L-Thymidine (FLT) PET Imaging in Children With Gliomas | withdrawn | — | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 12, 2019 | clinicaltrials |
| NCT00994071 | A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors | completed | Phase 1 | 9 | National Cancer Institute (NCI)NIH | 1 | Dec 9, 2019 | clinicaltrials |
| NCT01251913 | A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration for Research Purposes | terminated | — | 7 | National Cancer Institute (NCI)NIH | 1 | Dec 3, 2019 | clinicaltrials |